Pharmaceuticals & Biotech.    
SECTOR | 27 Nov 2020, 01:44PM
Business Standard
Pandemic puts AIDS-related gains at risk, Museum of London asks citizens to share Covid dreams, virus revives debate on value of high-stake exams, and other pandemic-related news across the globe
Nirmal Bang Institutional released a Sector Update report for Pharmaceuticals & Biotech. on 20 Nov, 2020.
Pharmaceuticals & Biotech.    
SECTOR | 26 Nov 2020, 11:29AM
Business Line
For every 100 seconds , one HIV case was reported in 2019
default
Pharmaceuticals & Biotech.    
SECTOR | 24 Nov 2020
Webinar with Indian Pharmaceuticals Management and ET Analysts on the covid pandemic and the Indian Pharma response. Listen to the full discussion.
Pharmaceuticals & Biotech.    
SECTOR | 24 Nov 2020
Business Line
According to researchers at Purdue University, a new therapy for influenza virus infections can also be effective against other pathogenic virus infec
Nirmal Bang Institutional released a Sector Update report for Pharmaceuticals & Biotech. on 20 Nov, 2020.
Pharmaceuticals & Biotech.    
SECTOR | 22 Nov 2020
Business Standard
Book review of FEVERS, FEUDS, AND DIAMONDS: Ebola and the Ravages of History
Nirmal Bang Institutional released a Sector Update report for Pharmaceuticals & Biotech. on 20 Nov, 2020.
Pharmaceuticals & Biotech.    
SECTOR | 20 Nov 2020
Nirmal Bang Institutional
Albuterol Inhaler - Lupin and Cipla are showing encouraging early trends- Cipla is at 10% share while Lupin, which launched it about a month back, has also ramped up to 4% share. Incumbents GSK (Ventolin) and Teva (Proair) have maintained their prescription volumes while Cipla and Lupin have gained from Perrigo's exit. Cipla's gain has also come from the cannibalization of Proventil brand and authorized generics' share, which is down 73% from pre generic levels. Cequa gaining share in Dry Eye market - Sun Pharma is consistently building prescription volume in Cequa with a 20% growth so far over its 2QFY21 weekly exit volume. Semglee (bLantus) yet to meaningfully reflect in market share Biocon launched biosimilar...
Nirmal Bang Institutional released a Sector Update report for Pharmaceuticals & Biotech. on 20 Nov, 2020.
Pharmaceuticals & Biotech.    
SECTOR | 19 Nov 2020
Business Today
Convalescent Plasma Therapy (CPT) or passive immunotherapy has been tried in the past for treatment of viral infections like H1N1, Ebola and SARS-CoV-1 etc
Nirmal Bang Institutional released a Sector Update report for Pharmaceuticals & Biotech. on 20 Nov, 2020.
Pharmaceuticals & Biotech.    
SECTOR | 18 Nov 2020
What is Chapare virus', the Ebola-like deadly virus capable of human-to-human transmission
What is Chapare virus', the Ebola-like deadly virus capable of human-to-human transmission
Moneycontrol
Experts believe Chapare virus is unlikely to convert into a pandemic like COVID-19, but say there are reasons to be alarmed about a potential outbreak.
Pharmaceuticals & Biotech.    
SECTOR | 17 Nov 2020
Business Line
The World Health Organization launched the Global Strategy to Accelerate the Elimination of Cervical Cancer and also released the first estimates of t
default
Nirmal Bang Institutional released a Sector Update report for Pharmaceuticals & Biotech. on 20 Nov, 2020.
Pharmaceuticals & Biotech.    
SECTOR | 17 Nov 2020
Prabhudas Lilladhar
IPM grew by 4% YoY in Aug-Oct after second consecutive growth month. Oct-20 data points indicate that IPM growth could be back at pre-COVID level as 1) IPM witnessed second consecutive month of strong growth, for the first...
Nirmal Bang Institutional released a Sector Update report for Pharmaceuticals & Biotech. on 20 Nov, 2020.